Higher proportions of patients in the low to middle income brackets were diagnosed with localized renal cell carcinoma in states allowing Medicaid expansion.
Progression-free survival longer and response rate greater for cabozantinib versus sunitinib in phase 2 trial in adults with PRCC.
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
CheckMate 9ER investigators assessed the efficacy of combination nivolumab and cabozantinib in the front-line sarcomatoid renal cell carcinoma (RCC) setting in an extended analysis.